Pharmacokinetic and mathematical outliers for drugs with active metabolites. Note I. Model independent analyses for pentoxifylline

Farmacia

Volumn 58, Issue 3, 2010, Pages 264-278

  Mircioiu, Constantin ^a   Ionica, Georgeta ^a   Danilceac, Ala ^a   Miron, Dalia ^a   Mircioiu, Ionut ^b   Radulescu, Flavian ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Biopharmacy and Pharmacol Res SA   (Romania)

Author keywords

Active metabolites; Outliers; Pentoxifylline pharmacokinetic

Indexed keywords

1 (3' CARBOXYPROPYL) 3,7 DIMETHYLXANTINE; 1 (5' HIDROXYHEXYL) 3,7 DIMETHYLXANTINE; DRUG METABOLITE; PENTOXIFYLLINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG ABSORPTION; DRUG FORMULATION; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOKINETICS; SINGLE DRUG DOSE; STEADY STATE;

EID: 77953894654     PISSN: 00148237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. rd edition, John Wiley, 1994.
2. Guideline of the investigation of bioequivalence, http://www.emea.europa. eu/pdfs/human/qwp/140198enrev1.pdf
3. Heinzel G., Woloszczak R., Thomann P., Pharmacokinetic and Pharmacodynamic Data Analysis System for PC, Gustav Fisher Verlag, New York, 1993.
4. Ings R.M.J., Nudemberg F., Burrows J.L., Bruce T.A., The pharmacokinetics of pentoxifylline in man when administered by constant intrvenous infusion, Eur J Clin Pharmacol, 1982, 23, 539-43. (Pubitemid 13223433)
5. Prasacu I., Mircioiu C., Sandulovici R., Enache F., Release of metoprolol from solid dosage forms. Choice and validation of theoretical model, Farmacia, 2009, 57(1), 89-98.
6. Niklasson M., Bjorkman S., Roth B., Jonsson M., Hoglumd P. Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans, Chirality, 14, 643-652, 2002.
7. Peterson T.C., Peterson M.R., Wornell P.A., Blanchard M.G., Gonzalez F.J., Role of CYP1A2 and CYP2E1 in the pentoxifylline ciprofloxacin drug interaction. Biochem Pharmacol. 2004, 68(2), 395-402.
8. Rizzo N., Hispard E., Dolbeault S., Dally S., Leverge R., Girre C., Impact of long-term ethanol consumption on CYP1A2 activity. Clin Pharmacol Ther. 1997; 62(5):505.
9. Sandulovici R., Prasacu I., Mircioiu C., Voicu V., Medvedovici A., Anuţa V., Mathematical and phenomenological criteria in selection of pharmacokinetic model for M1 metabolite of pentoxyphylline, Farmacia, 2009, 57(2), 235-246.
10. th edition, Marcel Dekker, New York, 2004.